Going abroad depends heavily on where the patient is based, their performance status (physical strength), and the specific biological target of the tumor.
When Going Abroad Makes Sense
Specialized Surgical & Local Regimens in East Asia: Countries like Japan and South Korea treat a vastly higher volume of gastric cancer than Western countries, leading to advanced surgical staging techniques and aggressive management protocols (such as conversion surgery after systemic therapy, or regional peritoneal washouts).
Access to Specific Clinical Trials: Certain novel targets (especially early-stage CLDN18.2 CAR-T cells and next-gen ADCs) have active phase I/II trials primarily in China, Japan, or select European centers.
Cost Differentials (Uninsured/Self-Pay): High-tier academic hospitals in South Korea, Germany, or Turkey can sometimes provide standardized multimodal therapy at significantly lower self-pay costs than private US healthcare.
Why Staying Local (or Seeking Domestic Centers) Is Often Superior
Standardization of Care: Major academic National Cancer Institute (NCI)-designated centers in the US, as well as top European cancer networks, already administer all standard first-line targeted therapies (zolbetuximab, pembrolizumab, trastuzumab deruxtecan) and have open clinical trials for next-gen agents.
Toxicity Management & Fragility: Stage IV stomach cancer frequently involves complications like gastrointestinal bleeding, obstruction, nausea, ascites, and rapid weight loss. Traveling long distances (especially international flights) carries severe risks of deep vein thrombosis, fatigue, infection, and sudden complications far from the treating team.
Continuity of Care: Systemic therapies are administered in cycles every 2 to 3 weeks. Sustaining international travel over months is logistically exhausting and can disrupt dose schedules.
Immediate Actionable Checklist
1. Demand Comprehensive Biomarker Testing: Ensure the pathology lab has evaluated the biopsy for HER2 status, PD-L1 (CPS score), MSI/MMR, and specifically Claudin 18.2 (CLDN18.2).
2. Consult a High-Volume Academic Center: Before committing to international travel, get a second opinion at a major comprehensive cancer center nearby. These institutions frequently have active clinical trial registries for bispecifics, CAR-T, or novel ADCs.
3. Involve Palliative & Nutritional Teams Early: In advanced gastric cancer, early palliative care focuses on symptom relief, pain management, and nutritional support (e.g., stenting or venting if obstruction occurs), which directly preserves physical performance and extends eligibility for systemic treatments.
For stage IV gastric (stomach) cancer, the top institutions on the West Coast are National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. These centers have dedicated Gastrointestinal (GI) Oncology Multidisciplinary Teams, extensive clinical trial pipelines (including CLDN18.2 therapies, novel bispecifics, and ADCs), and advanced peritoneal metastasis protocols.
UCSF Helen Diller Family Comprehensive Cancer Center
Focus: Nationally renowned gastrointestinal oncology program with high-volume clinical research.
Key Advantages:
Active participation in early-phase (Phase I/II) clinical trials investigating CLDN18.2 CAR-T, bispecific antibodies, and immunotherapy combinations.
Comprehensive multidisciplinary GI tumor boards involving specialized medical oncologists, surgical oncologists, and gastroenterologists for interventional stenting and symptom relief.
Stanford Medicine Cancer Center
Focus: Leaders in precision genomics, molecular oncology, and biomarker-matched targeted therapy.
Key Advantages:
Seamless integration with the Stanford Cancer Institute’s deep genomics and molecular pathology teams to identify rare actionable mutations.
Extensive trial network evaluating novel antibody-drug conjugates (ADCs) and cellular therapies for advanced gastroesophageal cancers.
UCLA Jonsson Comprehensive Cancer Center
Focus: World leaders in cancer immunotherapy and translational science.
Key Advantages:
Extensive clinical trials pairing checkpoint inhibitors with novel targeted agents for HER2-positive and Claudin 18.2-positive gastric cancers.
Robust supportive and integrative oncology services designed to maintain physical stamina and quality of life during intensive systemic therapy.
How to Approach These Centers
Expedited Second Opinions: Most of these centers offer formal second-opinion programs where medical records, pathology slides, and imaging can be reviewed by their gastrointestinal disease-specific tumor board without an immediate in-person trip.
Clinical Trial Navigators: When contacting any of these institutions, ask specifically for their GI Clinical Trials Coordinator to see which active stage IV gastric protocols are currently enrolling.